UCB’s Fintepla led to nearly 50% seizure reduction in CDD patients
With only one FDA-approved drug in CDD, UCB’s success is significant for patients’ hope of another marketed therapy.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
